In short
PIPE-791 is an investigational drug being studied for idiopathic pulmonary fibrosis (IPF), a progressive lung disease that causes scarring of the lungs. It is a lysophosphatidic acid receptor 1 (LPAR1) antagonist developed by Contineum Therapeutics. One Phase 2 clinical trial with 428 participants is currently authorised to test whether PIPE-791 can slow the decline in lung function compared to placebo.
Key points
- PIPE-791 is an investigational LPAR1 antagonist being studied for idiopathic pulmonary fibrosis (IPF).
- One Phase 2 clinical trial is authorised, with 428 participants planned.
- The trial compares PIPE-791 taken orally against a placebo.
- The main measure is the change in forced vital capacity (FVC) from baseline to week 26.
- The trial is currently authorised but not yet recruiting.
What is PIPE-791?
PIPE-791 is an investigational drug developed by Contineum Therapeutics, a company based in San Diego, California. It is a lysophosphatidic acid receptor 1 (LPAR1) antagonist, meaning it blocks the action of a specific receptor involved in scarring processes. PIPE-791 has not been approved as a medicine; it is still being studied in clinical trials.
How does PIPE-791 work?
PIPE-791 blocks the lysophosphatidic acid receptor 1 (LPAR1). Lysophosphatidic acid (LPA) is a signalling molecule that can activate this receptor and contribute to fibrosis, the formation of scar tissue. By blocking LPAR1, PIPE-791 aims to reduce the fibrotic process. In laboratory models of lung fibrosis, PIPE-791 produced antifibrotic effects, meaning it reduced the formation of scar tissue in the lungs.
Which conditions is it studied for?
- Idiopathic pulmonary fibrosis (IPF) — a chronic lung disease in which the lungs become progressively scarred, making it harder to breathe. The cause is unknown, which is what 'idiopathic' means.
How is PIPE-791 given?
PIPE-791 is given orally, meaning it is taken by mouth. The exact dose is not reported in the available trial registry data.
What do the clinical trials show?
One Phase 2 clinical trial is authorised for PIPE-791 in idiopathic pulmonary fibrosis. The trial is designed to include 428 participants. It compares PIPE-791 taken orally against a placebo.
The main measure in this trial is the change in forced vital capacity (FVC) from baseline to week 26. Forced vital capacity is the total amount of air a person can exhale after taking the deepest possible breath; a decline in FVC indicates worsening lung function. The trial aims to investigate whether PIPE-791 can slow this decline compared to placebo.
The trial is currently authorised but not yet recruiting participants.
What side effects are known?
No side effects have been reported in the available sources. The trial is still in an early stage, and safety information will emerge as the study progresses.